TG Therapeutics (TGTX) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

TG Therapeutics Revenue Highlights

Latest Revenue (Y)

$616.29M

Latest Revenue (Q)

$204.92M

Main Segment (Y)

Product

Main Geography (Y)

Worldwide

TG Therapeutics Revenue by Period

TG Therapeutics Revenue by Year

Date	Revenue	Change
2025-12-31	$616.29M	87.32%
2024-12-31	$329.00M	40.80%
2023-12-31	$233.66M	8290.02%
2022-12-31	$2.79M	-58.36%
2021-12-31	$6.69M	4300.66%
2020-12-31	$152.00K	-
2019-12-31	$152.00K	-
2018-12-31	$152.00K	-0.25%
2017-12-31	$152.38K	-
2016-12-31	$152.38K	-
2015-12-31	$152.38K	-
2014-12-31	$152.38K	-
2013-12-31	$152.38K	699.98%
2012-12-31	$19.05K	100.00%
2011-12-31	-	100.00%
2010-12-31	-	100.00%
2009-12-31	-	100.00%
2008-12-31	-	100.00%
2007-12-31	-	100.00%
2006-12-31	-	100.00%
2005-12-31	-	100.00%
2004-12-31	-	100.00%
2003-12-31	-	-100.00%
2002-12-31	$500.00K	-81.56%
2001-12-31	$2.71M	-49.39%
2000-12-31	$5.36M	346.58%
1999-12-31	$1.20M	-60.00%
1998-12-31	$3.00M	2900.00%
1997-12-31	$100.00K	-
1996-12-31	$100.00K	-

TG Therapeutics generated $616.29M in revenue during NA 2025, up 87.32% compared to the previous quarter, and up 405451.97% compared to the same period a year ago.

TG Therapeutics Revenue by Quarter

Date	Revenue	Change
2026-03-31	$204.92M	6.41%
2025-12-31	$192.57M	19.09%
2025-09-30	$161.71M	14.57%
2025-06-30	$141.15M	16.79%
2025-03-31	$120.86M	11.71%
2024-12-31	$108.19M	28.98%
2024-09-30	$83.88M	14.17%
2024-06-30	$73.47M	15.74%
2024-03-31	$63.47M	44.35%
2023-12-31	$43.97M	-73.48%
2023-09-30	$165.81M	931.57%
2023-06-30	$16.07M	106.00%
2023-03-31	$7.80M	9653.75%
2022-12-31	$80.00K	-14.89%
2022-09-30	$94.00K	-84.18%
2022-06-30	$594.00K	-70.54%
2022-03-31	$2.02M	-13.14%
2021-12-31	$2.32M	14.33%
2021-09-30	$2.03M	31.39%
2021-06-30	$1.54M	94.83%
2021-03-31	$793.00K	1986.84%
2020-12-31	$38.00K	-
2020-09-30	$38.00K	-
2020-06-30	$38.00K	-
2020-03-31	$38.00K	-
2019-12-31	$38.00K	-
2019-09-30	$38.00K	-
2019-06-30	$38.00K	-
2019-03-31	$38.00K	-
2018-12-31	$38.00K	-
2018-09-30	$38.00K	-
2018-06-30	$38.00K	-
2018-03-31	$38.00K	-0.25%
2017-12-31	$38.09K	-0.00%
2017-09-30	$38.10K	0.00%
2017-06-30	$38.09K	-
2017-03-31	$38.09K	-
2016-12-31	$38.09K	-0.00%
2016-09-30	$38.10K	0.00%
2016-06-30	$38.09K	-
2016-03-31	$38.09K	-
2015-12-31	$38.09K	-0.00%
2015-09-30	$38.10K	0.00%
2015-06-30	$38.09K	-
2015-03-31	$38.09K	-
2014-12-31	$38.09K	-0.00%
2014-09-30	$38.10K	0.00%
2014-06-30	$38.09K	-
2014-03-31	$38.09K	-
2013-12-31	$38.09K	-0.00%
2013-09-30	$38.10K	0.00%
2013-06-30	$38.09K	-
2013-03-31	$38.09K	99.99%
2012-12-31	$19.05K	100.00%
2012-09-30	-	100.00%
2012-06-30	-	100.00%
2012-03-31	-	100.00%
2011-12-31	-	100.00%
2011-09-30	-	100.00%
2011-06-30	-	100.00%
2011-03-31	-	100.00%
2010-12-31	-	100.00%
2010-09-30	-	100.00%
2010-06-30	-	100.00%
2010-03-31	-	100.00%
2009-12-31	-	100.00%
2009-09-30	-	100.00%
2009-06-30	-	100.00%
2009-03-31	-	100.00%
2008-12-31	-	100.00%
2008-09-30	-	100.00%
2008-06-30	-	100.00%
2008-03-31	-	100.00%
2007-12-31	-	100.00%
2007-09-30	-	-

TG Therapeutics generated $204.92M in revenue during Q1 2026, up 6.41% compared to the previous quarter, and up 189.41% compared to the same period a year ago.

TG Therapeutics Revenue Breakdown

TG Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
Royalty	$5.62M	$801.00K	-	-	-
License Revenue	$152.00K	$152.00K	$140.15M	-	-
Other Revenue	$3.59M	$1.82M	$1.50M	-	-
Product	$606.93M	$313.73M	$92.00M	-	-
Milestone	-	$12.50M	-	-	-
Product revenue, net	-	-	-	$2.63M	$6.54M
License revenue	-	-	-	$152.00K	$152.00K

TG Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 25: Product (98.48%), Royalty (0.91%), Other Revenue (0.58%), and License Revenue (0.02%).

Quarterly Revenue by Product

Product/Service	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21
Product	$201.31M	$189.11M	$159.32M	$138.84M	$119.66M	$179.94M	$83.30M	$50.49M	$66.94M	$25.07M	$1.51M	$755.00K	-	-	-	-	-	-	-	-
License Revenue	$3.61M	-	$2.39M	$2.31M	$38.00K	$76.00K	$38.00K	$38.00K	-	-	-	-	-	-	-	-	-	-	-	-
Royalty	-	$5.01M	$605.00K	$539.00K	$229.00K	$33.00K	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Revenue	-	$3.03M	$558.00K	$1.09M	$315.00K	$415.00K	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Milestone	-	-	-	-	-	-	$12.50M	-	-	-	-	-	-	-	-	-	-	-	-	-
License	-	-	-	-	-	-	-	-	-	$140.75M	$38.00K	$38.00K	-	-	-	-	-	-	-	-
License revenue	-	-	-	-	-	-	-	-	-	-	$38.00K	$38.00K	$38.00K	$38.00K	$38.00K	$38.00K	$38.00K	$38.00K	-	-
Product revenue, net	-	-	-	-	-	-	-	-	-	-	$16.04M	$7.76M	$42.00K	$56.00K	$556.00K	$1.98M	$2.28M	$1.99M	-	-

TG Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Mar 26: Product (98.24%), and License Revenue (1.76%).

TG Therapeutics Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 24	Dec 23
Worldwide	$313.73M	$92.00M
International	$3.71M	$3.22M

TG Therapeutics's latest annual revenue breakdown by geography, as of Dec 24: Worldwide (98.83%), and International (1.17%).

Quarterly Revenue by Country

Country	Mar 26	Sep 25
UNITED STATES	$194.80M	$152.90M

TG Therapeutics's latest quarterly revenue breakdown by geography, as of Mar 26: UNITED STATES (100.00%).

TG Therapeutics Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
PTCT	PTC Therapeutics	$1.73B	$272.55M
ALKS	Alkermes	$1.48B	$392.91M
ARWR	Arrowhead Pharmaceuticals	$829.45M	$73.74M
TGTX	TG Therapeutics	$616.29M	$204.92M
KRYS	Krystal Biotech	$389.13M	$116.36M
KYMR	Kymera Therapeutics	$39.20M	$34.37M
CRSP	CRISPR Therapeutics	$3.51M	$1.46M
PTGX	Protagonist Therapeutics	-	-
PCVX	Vaxcyte	-	-
IMVT	Immunovant	-	-
ACLX	Arcellx	-	$7.55M

TGTX Revenue FAQ

What is TG Therapeutics’s yearly revenue?

TG Therapeutics's yearly revenue for 2025 was $616.29M, representing an increase of 87.32% compared to 2024. The company's yearly revenue for 2024 was $329M, representing an increase of 40.80% compared to 2023. TGTX's yearly revenue for 2023 was $233.66M, representing an increase of 8290.02% compared to 2022.

What is TG Therapeutics’s quarterly revenue?

TG Therapeutics's quarterly revenue for Q1 2026 was $204.92M, a 6.41% increase from the previous quarter (Q4 2025), and a 69.56% increase year-over-year (Q1 2025). The company's quarterly revenue for Q4 2025 was $192.57M, a 19.09% increase from the previous quarter (Q3 2025), and a 78.00% increase year-over-year (Q4 2024). TGTX's quarterly revenue for Q3 2025 was $161.71M, a 14.57% increase from the previous quarter (Q2 2025), and a 92.79% increase year-over-year (Q3 2024).

What is TG Therapeutics’s revenue growth rate?

TG Therapeutics's revenue growth rate for the last 3 years (2023-2025) was 163.75%, and for the last 5 years (2021-2025) was 9113.44%.

What are TG Therapeutics’s revenue streams?

TG Therapeutics's revenue streams in c 25 are Royalty, License Revenue, Other Revenue, and Product. Royalty generated $5.62M in revenue, accounting 0.91% of the company's total revenue, up 601.00% year-over-year. License Revenue generated $152K in revenue, accounting 0.02% of the company's total revenue Other Revenue generated $3.59M in revenue, accounting 0.58% of the company's total revenue, up 97.04% year-over-year. Product generated $606.93M in revenue, accounting 98.48% of the company's total revenue, up 93.46% year-over-year.

What is TG Therapeutics’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of TG Therapeutics was Product. This segment made a revenue of $606.93M, representing 98.48% of the company's total revenue.